Embryonic stem (ES) 
Introduction

Embryonic stem (ES) cells are pluripotent cells derived from the inner cell mass of the blastocyst. Their ability to differentiate into any somatic cell type makes them ideally suited for the study of early developmental steps, but they also represent a promising source for future cell therapy. Although a heterogeneous mixture of different cell types derived from ES cells is easy to obtain in culture, their targeted differentiation towards a specific lineage remains
challenging. Even more difficult is to obtain cell populations which are synchronized at a particular differentiation stage [1] . [2] ). These approaches are cost-and labour intensive, and often result in the generation of heterogeneous cell populations. Transgenic expression of transcription factors has also been used to drive ES cell differentiation [3, 4] , but is hampered by the risk of malignant transformation upon integration of the transgene into the host cell genome. An alternative is the use of cell-permeant transcription factors, which has however been of limited efficacy so far [5] .
Methods to drive differentiation of ES cells include use of growth factors, coculture with stromal cells, and adhesion on specific extracellular matrix proteins (reviewed in
A more recent concept is the use of small molecules to control ES cell differentiation [6] [7] [8] [9] . Advantages [10] . The pENTR eGFP, pENTR mRFP1, pENTR EF1-␣S, pENTR T␣1 ␣-tubulin, 2K7bsd vectors, have been described before [11] . The 
Vector constructions
We previously described the construction of the 2K7GFP [13] . To generate the 2K7EFSGFP, the SV40 promoter sequence was replaced by the EF1-␣S promoter sequence. To generate the 2K7EFSRluc, the GFP coding sequence from 2K7EFSGFP was replaced by the Renilla luciferase coding sequence from pRL-CMV. The construction of pENTR mRFP1, pENTR T␣1 ␣-tubulin and pENTR Fluc were described before [11, 13] . The resulting entry vectors were then recombined into 2K7EFSGFP or 2K7EFSRluc lentivectors using the Gateway ® LR plus clonase enzyme mix.
Cell cultures and neuronal differentiation
CGR8 mouse ES cells and H1 human ES cells were cultured as described [11] [15] .
ES cell transductions
ES cell transductions were performed as previously described [11] 
Immunostaining quantification
Immunostaining and nuclear staining quantifications were performed using the MetaXpress software (Molecular Devices). Total neurite outgrowth was quantified using the neurite outgrowth analysis module, and total cell numbers were quantified with the count nuclei analysis module.
Quantitative analysis of cells expressing fluorescent proteins
For the studies investigating the activity of the T␣1 ␣-tubulin and the EF1-␣S promoter during neuronal differentiation of the CGR8EFSGFPT␣1mRFP1 cell line, fluorescence intensity of eGFP and mRFP1 in a given cell was quantified using the Metamorph ® software. Table S1 .
Real time PCR
Reactions were run on an ABI Prism 7900 HT detection system (Applied Biosystems, Rotkraz, Switzerland). ALAS and GusB were used as housekeeping genes. As these genes behaved similarly in all samples examined, data was normalized to ALAS level. Sequences of the primers are shown in
Results
Primary screening of neuronal differentiation of ES cells
We first developed a method to screen for small molecules that affect neural lineage commitment of ES cells. For this purpose, we
used the 2K7 lentivectors we recently described [11] Fig. 2A and B) . Fig. 2D and E) , with occasional neuronal networks (data not shown). After 10 weeks, further neuronal networks formed in phenazopyridine-treated cells (Fig. 2F) , but not in DMSO-treated cells (Fig. 2C) . To quantify neuronal differentiation, we chose to measure total neurite outgrowth and divided it by total cell number at different time-points in three independent experiments (Fig. 2G) 
␤3-tubulin and vimentin (
. Efficiency of differentiation of phenazopyridinetreated cells into mature neurons was variable, but always superior to DMSO-treated cells, as confirmed by Kruskal-Wallis analysis of ranks statistical analysis (P ϭ 0.045).
Next, we tested the activity of phenazopyridine on neuronal differentiation in a three-dimensional culture system [15] . At two different time-points (Fig. 2H) , we observed a significant increase in the total number of neural tubes when phenazopyridine was added to the culture medium. We conclude that phenazopyridine enhances neuronal differentiation of human ES cells. (Fig. 4A ), which were often containing typical rosette areas positive for nestin and ␤3-tubulin (Fig. 4B) , but there were also clusters negative for both markers (Fig. 4C) . Musashi, Pax6, Sox1, vimentin and GFAP were distributed heterogeneously (Fig. 4D-G Fig. 4I and J), Sox1 (Fig. 4M) and vimentin-positive (Fig. 4O) , expressed ␤3-tubulin (Fig. 4J) and Pax6 (Fig. 4M) at low levels, and were negative for musashi (Fig. 4L) . Cells therefore displayed a homogeneous distribution of neuronal markers, at the exception of few strongly ␤3-tubulinpositive (Fig. 4J) , and some GFAP ϩ cells (Fig. 4N) . Fig. 4H and 4P) . In DMSO-treated cells, all expression patterns were well represented (Fig. 4H) (Fig. 5A) (Fig. 4) .
Phenazopyridine permits the generation of homogeneous and synchronous populations of neuronal precursors
We next investigated the effects of phenazopyridine (3 M) using a differentiation protocol in which all components can be replaced © 2009 The Authors Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 2 Phenazopyridine enhances neuronal differentiation of human ES cells. Human ES cells were cultured for 6 weeks with phenazopyridine (PAP) at 3 M or DMSO only, and subsequently replated without further treatment. Cells were immunostained for neuronal markers at different time-points. (A)-(C): DMSO-treated cells. (D)-(F): phenazopyridine-treated cells. (G) quantification of neurite outgrowth divided by total cell number at different time-points. Blue: control-treated cells; purple: phenazopyridine-treated cells. Scale bars: 100 m. (H) quantification of neural tube number per threedimensional human ES cell neuronal differentiation culture after 2 weeks and 4 weeks of differentiation. White: control-treated cells; black: phenazopyridine-treated cells. **: P Ͻ 0.01. Error bars: standard error of the mean. by clinical grade equivalents (differentiation protocol 2, described in 'Materials and methods'). Figure 3 shows representative phase contrast pictures of human ES cells at different stages of differentiation. DMSO-treated and phenazopyridine-treated spheres were morphologically indistinct after 1 week of differentiation (Fig. 3A and F). At 2 weeks of differentiation, control spheres remained relatively compact (Fig. 3B), whereas phenazopyridine-treated spheres developed bigger areas of monolayer at their periphery (Fig. 3G). Interestingly, many mitotic figures and PCNA ϩ cells could be found in this area of phenazopyridine-treated cells, whereas only very few were present in DMSO-treated cells (data not shown). After mechanical passaging, cells remained as aggregates in DMSO-treated cells (Fig. 3C and D) while phenazopyridine-treated cells (Fig. 3H and I) could easily be dissociated into single cells. These observations were also confirmed in the HS401 cell line (Fig. 3E and J). Interestingly, there was a marked difference between the percentages of living single cells in control cells compared to phenazopyridine-treated cells as assessed by trypan blue staining at different time-points throughout the procedure (Fig. 3K). This suggests that phenazopyridine favours cell growth in monolayers and promotes survival of dissociated cells. To investigate the phenotype of control and phenazopyridinetreated cells, we performed immunostainings for several neuronal markers after 4 weeks of differentiation in three independent experiments. Control-treated cells were mainly present as clusters
). In contrast, phenazopyridine-treated cells were mainly present as isolated cells, with only very few small clusters. Virtually all cells were nestin (
To quantify the synchronization of the cell population induced by phenazopyridine, we counted the number of cells negative for nestin and ␤3-tubulin (non-neural cells), positive for nestin with low levels of ␤3-tubulin (early neuronal precursors), positive for both markers at high levels (young neurons), or expressing ␤3-tubulin only (differentiated neurons) (
Fig. 3 Effect of phenazopyridine in the second neuronal differentiation protocol of human ES cells. (A)-(J): phase contrast pictures of control (A-E) and phenazopyridine (FϪJ) treated cells (3 M) at different timepoints. (A)-(D) and (F)-(I): H1 human ES cells. (E) and (J): HS401 ES cells. (K): percentage of living single cells by trypan blue exclusion at different timepoints in control (white bars) or phenazopyridine-treated cells (black bars
Phenazopyridine accelerates emergence of early neuronal markers and decreases markers of undifferentiated and non-neural cells
We next investigated the kinetics of emergence of neural and nonneural markers in DMSO and 3 M phenazopyridine-treated H1 ES cells by real time PCR. After 2 weeks of differentiation, we observed an up-regulation of markers of early neuronal differentiation (Pax6, nestin), intermediate (␤3-tubulin, vimentin) and late differentiation (␤3-tubulin, Map2) in phenazopyridine-treated cells as compared to control cells
We then investigated expression of non-neural markers. Unexpectedly, after 2 weeks of differentiation, Oct-4 (marking undifferentiated ES cells) and brachyury (marking early mesoderm) were increased in phenazopyridine-treated cells, and ␣-fetoprotein (AFP, marking primitive endoderm) did not vary between both conditions (Fig. 5B). We reasoned that the persistence of these markers could be temporary and therefore investigated their expression after 4 weeks © 2009 The Authors Journal compilation © 2009 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 4 Phenazopyridine treatment allows the generation of a homogenous monolayer of synchronized neuronal precursors. Human ES cells were cultured for 4 weeks using the differentiation protocol 2 (see 'Materials and methods'), treated with DMSO alone or phenazopyridine (3 M). Cells were subsequently immunostained for markers of neuronal differentiation and for alkaline phosphatase, marking undifferentiated ES cells. (A)-(G): DMSO-treated cells. I-O: phenazopyridine-treated cells (PAP). (F) and (M) show DAPI staining corresponding to the fields shown in E and L, respectively. Scale bars: 100 m. (H) and (P): quantification of cells expressing different markers in DMSO-treated cells (H) and phenazopyridine-treated cells (P). Error bars: standard error of the mean. of differentiation. Indeed, all three markers were markedly downregulated in phenazopyridine-treated cells (Ͼ1000-fold for Oct4
and ␣-fetoprotein, and Ͼ10-fold for brachyury; Fig. 5C )
. These results suggest that (i ) phenazopyridine accelerates the emergence of neural markers and that (ii ) 4 weeks of treatment with phenazopyridine decreases the amount of undifferentiated and non-neural cells.
Phenazopyridine-treated cells can differentiate into all three neural lineages
To investigate the potential of neuronal precursors generated through phenazopyridine treatment, we devised a two step differentiation protocol. [17] . In control-treated cells after 1 week of differentiation, we observed a heterogeneous cell population: neuronal networks in some regions (Fig. 6A1) juxtaposed to areas containing tightly packed neuronal precursors (Fig. 6A2) , and very few isolated cells positive for Sox1 and occasionally for Pax6 (Fig. 6A3) (Fig. 6C1) , alkaline phosphatasepositive cell areas (Fig. 6C2) (Fig. 6A4-6 ). We analysed subtypes of neurons in the phenazopyridine-treated cells and observed glutamatergic (Fig. 6B1) , GABAergic (Fig. 6B2) and -more rarely -TH ϩ neurons (Fig. 6B3) (Fig. 6C4-7) , together with more mature neurons, astrocytes and oligodendrocyte progenitors ( Fig. 6D1-2) . The majority of cells were belonging to the neuronal [6] [7] [8] [9] [18] [19] [20] . So far, such approaches have been applied to mouse ES cells and molecules which maintain cells in an undifferentiated state [8, 20] or enhance their differentiation [6, 9, 20] have been described. One study demonstrated that the GSK-3␤ inhibitor TWS119 enhanced neuronal differentiation of mouse ES cells [6] [6, 9] , our system allows the activity of the neuronal promoter to be normalized and therefore allows the extent of neuronal differentiation and the size of the cell population analysed to be discriminated. The use of the 2K7 lentivector system [11] urinary tract mucosa [21] 
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